Table 3 Sensitivity and specificity of 5 novel recombinant antigens by dot-blot assay [PTB = 111, EPTB = 29 and controls = 110].
Sensitivity [n (%; 95% CI)] | Specificity [n (%; 95% CI)] | PPV (%) | NPV (%) | LRP (95% CI) | DA %, (95% CI) | |
|---|---|---|---|---|---|---|
PTB cases (n = 111) | ||||||
rSS5 (Rv2970c) | 110/111 (99.1%; 95.1, 99.8) | 108/110 (98.2%; 93.6, 99.6) | 98.2% | 99.1% | 54.5 (20.4–145.2) | 98.6% (96.1, 99.5) |
rSS1 (Rv2145c) | 110/111 (99.1%; 95.1, 99.8) | 110/110 (100%; 96.6, 100) | 100% | 99.1% | − | 99.5% (97.5, 99.9) |
rSS4 (Rv1827) | 109/111 (98.2%; 93.7, 99.5) | 103/110 (93.6%; 87.4, 96.9) | 94.0% | 98.1% | 15.4 (11.6–20.4) | 95.9% (92.4, 97.8) |
rSS2 (Rv0164) | 107/111 (96.4%; 91.1, 98.6) | 102/110 (92.7%; 86.3, 96.3) | 93.0% | 96.2% | 13.2 (10.4–16.9) | 94.6% (90.7, 96.9) |
rSS3 (Rv1437) | 104/111 (93.7%; 87.5, 96.9) | 98/110 (89.1%; 81.9, 93.6) | 89.7% | 93.3% | 8.6 (7.3–10.1) | 91.4% (87.0, 94.4) |
Esat6 Ag | 95/111 (85.6%; 77.9, 90.9) | 73/110 (66.4%; 57.1, 74.51) | 72.0% | 82.0% | 2.5 (2.4–2.7) | 76.0% (70.0, 81.2) |
38 kDa Ag | 95/11116 (85.6%; 77.9, 90.9) | 60/110 (54.5%; 45.2, 63.5) | 65.5% | 78.9% | 1.9 (1.8–2.0) | 70.1% (63.8, 75.8) |
EPTB cases (n = 29) | ||||||
rSS5 (Rv2970c) | 28/29 (96.5%; 82.8, 99.4) | 108/110 (98.2%; 93.6, 99.6) | 93.3% | 99.1% | 53.1 (19.9–141.8) | 97.8% (93.8, 99.3) |
rSS1 (Rv2145c) | 27/29 (93.1%; 78.0, 98.1) | 110/110 (100%; 96.6, 100) | 100% | 98.2% | — | 98.6% (94.9, 99.6) |
rSS4 (Rv1827) | 27/29 (93.1%; 78.0, 98.1) | 103/110 (93.6%; 87.4, 96.9) | 79.4% | 98.1% | 14.6 (11.0–19.5) | 93.5% (88.1, 96.6) |
rSS2 (Rv0164) | 25/29 (86.2%; 69.4, 94.5) | 102/110 (92.7%; 86.3, 96.3) | 75.8% | 96.2% | 11.8 (9.2–15.3) | 91.4% (85.5, 95.0) |
rSS3 (Rv1437) | 26/29 (89.7%; 73.6, 96.4) | 98/110 (89.1%; 81.9, 93.6) | 68.4% | 97.0% | 8.2 (6.9–9.8) | 89.2% (83.0, 93.3) |
Esat6 Ag | 21/29 (72.4%; 54.3, 85.3) | 73/110 (66.4%; 57.1, 74.51) | 36.2% | 90.1% | 2.1 (2.0–2.3) | 67.6 (59.5–74.8) |
38 kDa Ag | 25/29 (86.2%; 69.4, 94.5) | 60/110 (54.5%; 45.2, 63.5) | 33.4% | 93.7% | 2.0 (1.8–2.0) | 61.1% (52.8, 68.8) |
MDR-TB Cases [(n = 50) | ||||||
rSS5 (Rv2970c) | 50/50 (100%; 92.9, 100) | 108/110 (98.2%; 93.6, 99.6) | 96.1% | 100% | 55.0 (20.6–146.5) | 98.7% (95.6, 99.7) |
rSS1 (Rv2145c) | 50/50 (100%; 92.9, 100) | 110/110 (100%; 96.6, 100) | 100% | 100% | — | 100% (97.7, 100) |
rSS4 (Rv1827) | 50/50 (100%; 92.9, 100) | 103/110 (93.6%; 87.4, 96.9) | 87.7% | 100% | 15.7 (11.9–20.8) | 95.6% (91.2, 97.9) |
rSS2 (Rv0164) | 50/50 (100%; 92.9, 100) | 102/110 (92.7%; 86.3, 96.3) | 86.2% | 100% | 13.7 (10.8–17.6) | 95.0% (90.4, 97.4) |
rSS3 (Rv1437) | 50/50 (100%; 92.9, 100) | 98/110 (89.1%; 81.9, 93.6) | 80.6% | 100% | 9.2 (7.8–10.8) | 92.5% (87.3, 95.7) |
Esat6 Ag | 45/50 (90.0%;78.6, 95.6) | 73/110 (66.4%; 57.1, 74.51) | 54.9% | 93.6% | 2.7 (2.5–2.8) | 73.7% (66.4, 79.9) |
38 kDa Ag | 47/50 (94.0%;83.8, 97.9) | 60/110 (54.5%; 45.2, 63.5) | 48.4% | 95.2% | 2.1 (2.0–2.2) | 66.9% (59.3, 73.7) |
